Figure 5.

Identified antibody variants display increased affinity and high conformational specificity for Aβ fibrils.A, concentration-dependent binding of selected antibody variants to immobilized Aβ fibrils. B, apparent affinity (EC₅₀) of selected antibody variants for Aβ fibrils. C, binding analysis of antibodies (30 nM) preincubated with different concentrations of disaggregated Aβ prior to binding to immobilized Aβ fibrils. D, percentage of bound antibody to Aβ fibrils for antibodies (30 nM) preincubated with disaggregated Aβ (1000 nM). In (A–D), clinical-stage Aβ antibodies (aducanumab and crenezumab) were used for comparison, the results are average values, and the error bars are standard deviations (two independent repeats).